主页 > 医学动态 >
【drug-news】六千突变---新药筛选之利器！
A major challenge in drug discovery is to identify the cellular targets responsible for the pharmacological activity of drug candidates. In the yeast Saccharomyces cerevisiae, a heterozygous diploid mutant collection of ~6000 strains, in each of which one copy of a single gene is deleted, is commercially available. With this collection, it is possible to evaluate the role of each gene product in the response of cells to a drug. Drug-induced haploinsufficiency refers to the situation where a heterozygous diploid mutant is more sensitive to a drug than is the wild-type strain. Drug-induced haploinsufficiency screening has the potential to reveal pharmacological targets of drugs and those that contribute to undesired side effects, as well as gene products involved in drug transport, metabolism, or resistance. Using published studies, I present advantages and limitations of this technique and discuss its value for predicting drug targets in human cells.
全文在http://stke.sciencemag.org/cgi/content/abstract/scisignal.134pt5，权限所致，未能拿到。。。 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-31 05:11
医学,生命科学网